Back to today’s briefing

Story perspectives

Nuevocor Secures $45M to Advance Heart Disease Trials

5/6/2025

49 6

Summary

Story summary

Nuevocor, a pioneering biotechnology company from Singapore, has raised an impressive $45 million in Series B funding to propel its Phase 1/2 clinical trial of NVC-001, targeting the genetic heart condition LMNA DCM. This significant investment, co-led by Kurma Partners and Angelini Ventures, will fuel global clinical efforts and the establishment of a new office in Paris.

1 of 1

Story summary

Nuevocor, a pioneering biotechnology company from Singapore, has raised an impressive $45 million in Series B funding to propel its Phase 1/2 clinical trial of NVC-001, targeting the genetic heart condition LMNA DCM. This significant investment, co-led by Kurma Partners and Angelini Ventures, will fuel global clinical efforts and the establishment of a new office in Paris.